Taking stock of the drug industry, from the lab to the medicine chestApril 21, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Charles McQuillan/Getty Images STAT+ | In Ireland, a global hub for the pharma industry, Trump tariffs are a source of deep worry As the country braces for possible investment losses following any new levies, drugmakers see their own reasons for concern. By Andrew Joseph STAT+ | Gilead says its therapy delayed growth of tumors in aggressive form of breast cancer The therapy, used in combination with Keytruda, could provide a new option for women with newly diagnosed, metastatic, triple-negative breast cancer. By Adam Feuerstein STAT+ | When should six drugs count as one? The answer could be a big deal for pharma companies The strategy by the Danish drugmaker could have implications for which other medications are swept up in the negotiation process. By John Wilkerson MICHAEL MATHES/AFP via Getty Images STAT+ | NIH bans all future grants to universities with DEI programs or Israel boycotts The new rules escalate the Trump administration's campaign to force universities to end DEI programs and combat antisemitism By Anil Oza STAT+ | Immunovant replaces CEO, makes other changes as Roivant tightens control Immunovant was spun out of Roivant Sciences in 2019 to develop a pipeline of drugs to treat autoimmune disorders. By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments